Exhibitor Registration & Set-up
  8:00  General Registration & Breakfast
  8:30  Welcoming Remarks
  8:45  Keynote Presentation
  9:30  Innovation Plenary Session
10:45  Exhibits and Networking
11:30  Commercialization Plenary Session
12:45  Lunch with Table Host Experts
  2:00  Financing Plenary Session
  3:30  Closing Remarks

Keynote Speaker

        Rachel King
        CEO, Glycomimetics, Inc.
        Rachel King is co-founder and CEO of GlycoMimetics, Inc. (GMI), a biotechnology company which raised over $60 million in venture capital financing, entered into a major strategic partnership with Pfizer, and went public in early 2014.  Before founding GMI, she was an Executive in Residence at New Enterprise Associates, one of the nation’s leading venture capital firms.  Mrs. King came to NEA after serving as a Senior Vice President of Novartis Corporation.  Before joining Novartis, Mrs. King spent ten years with Genetic Therapy, Inc. through the company’s early stage, initial public offering, and eventual sale to Novartis.  After the sale to Novartis, she was named CEO and ran the company as a wholly owned subsidiary of Novartis.   She received her B.A degree from Dartmouth College and her MBA from Harvard Business School.  Mrs. King currently serves as Chair of the Board of the Biotechnology Industry Association (“BIO”).  She is also Chair of the Maryland Life Sciences Advisory Board appointed by Governor Martin O’Malley.

Back to Top

Innovation Plenary Panel

       Steven Marquis
       Senior Licensing Associate, Technology Transfer Office, Naval Research Laboratory
       Steven Marquis is a Senior Licensing Associate in the Technology Transfer Office at the Naval Research Laboratory, negotiating Patent License Agreements, Government Purpose Licenses, and Non-Disclosure Agreements. Mr. Marquis has 16 years as a Senior Technology Transfer Specialist at the NIH’s National Cancer Institute, Technology Transfer Center, where he served as the head of TTC’s office. He led the office in negotiating Collaborative Research and Development Agreements (CRADA), Material Transfer Agreements (MTA), Confidential Disclosure Agreements (CDA), and Clinical Trial Agreements (CTA). Prior, Mr. Marquis served as a Patent Examiner at the United States Patent and Trademark Office, examining applications in the fields of batteries, fuel cells, and electrochemical applications. Mr. Marquis has a BS in Chemical Engineering.

       Chris Vizas
       Chairman & CEO, SmartSenseCom
       For more than three decades, Mr. Vizas has been part of leadership teams developing successful companies in telecommunications, IT and energy services. He was a founder in Trinity Cellular, Orion Network Systems, Asia Pacific Space and Communications, Quo Vadis International, and Fiber Optic Sensor Systems. He served in the Ford White House Office of Telecommunications Policy, advised the Carter White House, was Special Counsel to the US Privacy Commission; he has also represented the U.S. in international conferences and negotiations and served over the past four decades on governmental advisory committees. He is currently Chairman of SmartSenseCom, Inc., a director of Sutton Hoo Studios, and a director of Agingo Corp. He is a member of the Board of the Center for International Business Education and Research at the George Washington University and was a co-founder of its Global and Entrepreneurial Finance Institute. He is a fellow of Branford College, Yale University, received his undergraduate, graduate and legal education at Yale, and spent two post graduate years as a Humanities Fellow at the University of Chicago.

        Gerg Merril
        CEO, Brain Sentry
       Greg Merril is an experienced entrepreneurial executive. He is CEO of Brain Sentry, Inc. and has served as founding CEO for two previous VC-backed fast growth health-related product companies. Brain Sentry is a leader in the development and commercialization of wearable sensors for head impact detection in football, lacrosse and hockey.  As founding CEO of HT Medical Systems he led the Company through a $42 million merger with Immersion Corp (NASDAQ: IMMR). He is an author on numerous peer reviewed technical papers and an inventor with nineteen issued patents. He successfully championed a Congressional appropriation funding a stimulaion-based medical training and certification initiative. He served as invited guest editor for the Proceedings of the IEEE Special Issue on Virtual and Augmented Reality in Medicine. He served as Principal Investigator on numerous federally funded research grants and as a referee/reviewer for government-sponsored and non-profit grants related to medical informatics and virtual reality technologies.

        Steven Sidel
        CEO, Mindoula
        Steve Sidel is a proven business builder and leader with a record of growing successful traditional and digital businesses across a range of industries, and an expert in driving rapid distribution of traditional media and new media products and platforms for both B-to-B and B-to-C companies. Steve is Founder & CEO of Mindoula Health, an innovative Bethesda-based behavioral health case management company providing 24/7 multi-platform support to people struggling with mental illness.  Steve is the former President, Discovery Education; Deputy General Counsel, Discovery Communications; Managing Director, Antenna Audio; and CEO, Edline.  He is a graduate of Brown University and Harvard Law School, and a Certified Peer Support Specialist.

        Richard O. Cliff
        VP, COO, Cellphire, Inc.
        Richard Cliff is a co-founder of both Adlyfe and Cellphire and currently serves as the COO of Cellphire. With Cellphire he was the Principal Investigator on a DARPA contract for the use of stabilized platelets for advanced wound repair.  Previously Mr. Cliff was with Geo-Centers, Inc. from 1987 to 2004 where he held several titles. While at Geo-Centers he was responsible for the process and product development of an advanced blood substitute product for the US Navy, along with management of a $15 million technical services contract with the Naval Research Laboratory Bio/Molecular Engineering Center. In 2000-2004, Mr. Cliff was an affiliate Assistant Professor at George Mason University where he initiated efforts in Biomaterials/Tissue Engineering technology within the Shared Resource Instrumentation Facility (SRIF).  Mr. Cliff received his B.S. in Biological Sciences from the George Washington University and an Executive Masters in Technology Management from the Wharton School of Business and the School of Engineering and Applied Science at the University of Pennsylvania.

Back to Top

            Mojdeh Bahar
            Assistant Administrator for Technology Transfer, Agricultural Research Service, USDA
            Ms. Bahar serves as the Assistant Administrator for Technology Transfer at the Agricultural Research Service, United States Department of Agriculture. She is responsible for managing the intellectual property that evolves from the research program of the Agency. She leads ARS's interactions on matters dealing with intellectual property and technology transfer. Ms. Bahar comes to ARS from NIH, where she served as the Chief of the Cancer Branch at the Office of Technology Transfer. She currently serves as a member on the FLC Executive Board. Ms. Bahar is also a Certified Licensing Professional (CLP).  She received a Master of Arts degree from New York University and a B.S. degree with Honors in Chemistry and French from Dickinson College.


Commercialization Plenary Panel

              Gary Fanger
 CEO, RadioRx
              Gary Fanger is currently Acting CEO for RadioRx, a cancer therapeutics development company, and serves as a director on the boards of Virtici and Envisage.  He has over 17 years of experience in the biotechnology industry developing novel therapeutics, establishing drug development alliances, and leading M&A activities. As Senior Vice President and Chief Operating Officer at Amplimmune, he helped to lead the $500 million acquisition by Medimmune/AstraZeneca in 2013.  Prior to joining Amplimmune, Dr. Fanger was Vice President of Business Development at MacroGenics where he directed partnering activities that included establishing MacroGenics’ strategic alliance with Eli Lilly & Company. Before MacroGenics, Dr. Fanger was responsible for a diverse array of corporate functions at Corixa Corporation, including heading up business development activities, establishing and directing the therapeutic antibody development program, and managing numerous partnerships. Dr. Fanger has co-authored over 45 articles, book chapters and reviews in peer-reviewed journals in the areas of monoclonal antibody development, cell biology and cancer research. He has also been awarded 35 patents. Dr. Fanger received his MBA from Seattle University, PhD in Molecular and Cellular Biology from Dartmouth Medical School, and his BS in Chemistry from Denison University.

              Eric Victory
              Eric Victory is Vice President & Head for cardiovascular, metabolic, and infectious disease within the MedImmune Partnering & Strategy group. His responsible for leading the company’s per-POC biologic externalization activities in two therapeutic areas. Eric has successfully closed the acquisitions of Spirogen and Amplimmune and key agreements with Advaxis, Immunocore, ADC Therapeutics and NGM Biopharmaceuticals.
              Prior to taking the Partnering and Strategy role in 2013, Eric was part of the MedImmune Corporate Development and Ventures team since 2011, with responsibility for business development and licensing transactions with institutions and in the cardiovascular, gastrointestinal, and metabolic disease therapeutic area, as well as oversight of MedImmune’s pandemic influenza contracts with the U.S. Government. Eric joined MedImmune in 2002 as a Product Manager in MedImmune’s Marketing Department and worked on Synagis (palivizumab), CytoGam (CMV-IVIG) and RespiGam (RSV-IVIG). In 2006 Eric joined MedImmune’s Business Development Department where he has worked on licensing transactions. Eric holds undergraduate degrees in physics and political sciences from Stanford University, and an MBA from Northwestern University’s Kellogg School of Management.   

               Wes Blakeslee
               Wes Blakeslee is Principal of a consulting and legal organization, Blakeslee, LLC., providing legal, consulting and recruiting services to universities, university startups, corporations, inventors and entrepreneurs in matters of Technology Transfer, intellectual property, policy, business formation,  moving technology to market, and sourcing qualified tech transfer and general counsel office personnel.
               Wes spent more than 15 years at The Johns Hopkins University.  He began as an Associate General Counsel, where he practiced intellectual property and complex business law.  He also taught APatents, Trademarks and Copyrights@ and ALaw, Intellectual property and the Information Age.  He was the lead University attorney in negotiations acquiring a university and health system wide enterprise management software system.  His expertise includes copyright fair use, complex sponsored research and collaboration agreements, material transfer agreements, intellectual property agreements, export controls, university policies, corporate formation, mergers and acquisitions. In 2006, Wes was requested to become Executive Director of Johns Hopkins Technology Transfer, where he led a formerly struggling office to seven consecutive years of growth, turning the office into one of the strongest in the US. 
              Wes holds an Engineering Degree (with Honors) from the Pennsylvania State University, and a Law Degree (Order of the Coif B With Honor), from the University of Maryland School of Law and is a Certified Licensing Professional.  In 2013 he was named Engineering Alumnus of the Year from the Department of Engineering Science and Mechanics, the highest honor bestowed by the Penn State Engineering School.

              Courtney Silverthorn, Ph.D
               Dr. Courtney Silverthorn is a Senior Interagency Policy Specialist at the National Institute of Standards and Technology. She has accumulated a federal tech transfer background through several positions, first as a fellow in the National Cancer Institute’s Technology Transfer Center, and then at the Frederick National Laboratory for Cancer Research, the FFRDC operated by Leidos Biomedical Research, on behalf of the National Cancer Institute, through the Intellectual Property Office and the Partnership Development Office. She currently serves as the Host Agency Representative on the Federal Laboratory Consortium’s Executive Board. Dr. Silverthorn holds a Ph.D. in Pharmacology from The Johns Hopkins University School of Medicine and a B.S. in Biochemistry and Molecular Biology from Sweet Briar College.

Back to Top

Financing Plenary Panel

        Abhishek Motayed
N5 Sensors
         Dr. Abhishek Motayed is an assistant research scientist at the Institute for Research in Electronics and Applied Physics at the University of Maryland, College Park. He has over 10  years of experience in the field of semiconductor devices, specializing in wide-bandgap materials/devices, low-dimensional semiconducting structures, micro/nanofabrication, device modeling and characterization. Dr. Motayed received his PhD in 2007 from the University of Maryland in Electrical and Computer Engineering. In 2012 he founded N5 Sensors, Inc. to commercialize the hybrid sensor technology licensed from University of Maryland. N5 Sensors currently has 5 full-time employees and several SBIR contracts.

        Alastair Mackay
Maryland Venture Fund
        Alastair Mackay joined the Maryland Venture Fund in April 2013. As Senior Life Sciences Principal, he reviews investment opportunities. Prior to signing with the MVF, he spent seven years providing expert coverage of public companies in the biotech, life science tools, medical devices, and molecular diagnostics industries for the institutional clients of GARP Research and Securities. His mandate was to identify and track companies that could fuel sustained earnings growth by developing and marketing high-value products. From 1996 to 2005, Mackay was a scientist/manager at Osiris Therapeutics, where he studied the differentiation of adult human stem cells while writing grants, contracting outside research, and preparing regulatory filings on stem cell therapies for arthritis, heart attacks, and spinal cord injury. Mackay's postdoctoral training was at the Johns Hopkins School of Medicine, where he cloned and sequenced an essential protein of the chromosome to discover its function. Mackay earned his PhD at the University of Vermont by studying on how asbestos exposure leads to lung cancer. He received a B.A. in Earth Sciences from Dartmouth College.

        Henry Ahn
        Mr. Ahn manages the Technology Commercialization Fund (TCF) for TEDCO, a seed funding program recognized by Entrepreneur Magazine as the nation’s most active early stage investor. Prior to joining TEDCO, Mr. Ahn was a technology licensing associate at Upstate USA, Inc. (now a Merck company), where he was involved with various aspects of technology transfer/licensing and supplier relations with government and academic institutions around the world. Additionally, Mr. Ahn has a total of five years of research experience in the field of immunology and he has been involved with several start-ups and other start-up activities in the Houston area. Mr. Ahn is involved with various organizations in the region, serving on a selection committee and/or acting as a coach/judge for Early Stage East, University of Maryland Business Plan Competition, MidAtlantic Bio, and INNoVATE. Mr. Ahn also serves on the advisory board for various incubators including the Maryland Center for Entrepreneurship, Rockville Innovation Center and Silver Spring Innovation Center. Mr. Ahn has an M.B.A. from Rice University, an M.S. in biotechnology from the University of Tennessee, Knoxville, and a B.S. in biomedical engineering from Boston University

          Judy Britz  
          BioMaryland Center
          Dr. Judith Britz joined the BioMaryland Center, a division within Maryland’s Department of Business and Economic Development, as its first Executive Director in January 2010.  Dr. Britz spent 10 years in academics and 25 years in industry, 15 as an entrepreneur of two startup companies, Sienna Biotech and Cylex Inc.  She raised >$50M for these two companies from strategic investors, venture capital, government and angel sources to bring products through the FDA process to market.  Dr. Britz also held senior management positions at Becton Dickinson, Johnson and Johnson (Ortho Diagnostics Systems, Inc.) and Electro-Nucleonics, Inc. where she successfully developed one of the first commercial blood screening tests for the AIDS virus.
         Dr. Britz’s academic credentials include a PhD in Immunology and Microbiology from Stanford University, a Master’s degree from MIT and her B.S from Goucher College.  She has held postdoctoral positions at Johns Hopkins and Yale medical schools.

Back to Top


BioHealth Innovation
Federal Laboratory Consortium for Technology Transfer
Food and Drug Administration
Ft. Detrick Alliance
Foundation for Advanced Education in the Sciences
Maryland Small Business Development Center
Montgomery College Workforce Development & Continuing Education
Montgomery County Department of Economic Development
National Institute of Standards and Technology/Technology Partnerships Office
National Security Agency Technology Transfer Program
Naval Research Laboratory
Northrop Grumman
Office of Research and Technology Applications, US Army Medical Research and Materiel Command
Rockville Economic Development Inc.
University of Maryland Office of Technology Commercialization
U.S. Department of Agriculture, Agriculture Research Service 


Table Hosts

BioHealth Innovation - Ethan Byler
BioMaryland Center - Judy Costello
Blakeslee, LLC - Wes Blakeslee
Cellphire - Richard Cliff
Federal Laboratory Consortium - Dr. Courtney Silverthorn
Johns Hopkins University Office of Technology Transfer - Ami Gadhia
Maryland Venture Fund - Alastair Mackay
MedImmune - Eric Victory
Mindoula - Steve Sidel
Montgomery College WD & CE - Steve Greenfield
Naval Research Laboratory - Steven Marquis
       & NAVSEA/NSWX -Carderock - Alyssa Littlestone
NIH Office of Tech Transfer - Steve Freguson
NIST Technology Partnerships Office - Paul Zielinski
Northrop Grumman - John Long
RadioRx - Gary Fanger
TEDCO - Ron Kaese
USDA Agricultural Research Service - Dr. Robert Griesbach

Back to Top